DEPO-TESTOSTERONE
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $6,400 | 2 | 1 |
| 2022 | $990.00 | 3 | 3 |
| 2020 | $934,807 | 11 | 0 |
| 2019 | $956,289 | 18 | 0 |
| 2018 | $6,750 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.9M | 35 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 1 OPENLABEL RANDOMIZED 2TREATMENT 2PERIOD SINGLEDOSE CROSSOVER STUDY 2PART DESIGN TO EVALUATE THE BIOEQUIVALENCE AND TOLERABILITY OF TESTOSTERONE CYPIONATE FOLLOWING INTRAMUSCULAR IM INJECTION IN HEALTHY HYPOGONADAL MALE SUBJECTS | PFIZER INC. | $1.9M | 0 |
| DEXMEDETOMIDINE PARECOXIB SODIUM LOW MOLECULAR WEIGHT HEPARIN SODIUM SALT TESTOSTERONE CIPIONATE MULTI PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $6,400 | 1 |
| HOSPITAL BRANDS CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $990.00 | 3 |
Top Doctors Receiving Payments for DEPO-TESTOSTERONE
Manufacturing Companies
- PFIZER INC. $1.9M
Product Information
- Type Drug
- Total Payments $1.9M
- Total Doctors 4
- Transactions 35
About DEPO-TESTOSTERONE
DEPO-TESTOSTERONE is a drug associated with $1.9M in payments to 4 healthcare providers, recorded across 35 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2018 to 2024. In 2024, $6,400 was paid across 2 transactions to 1 doctors.
The most common payment nature for DEPO-TESTOSTERONE is "Unspecified" ($1.9M, 100.0% of total).
DEPO-TESTOSTERONE is associated with 3 research studies, including "A PHASE 1 OPENLABEL RANDOMIZED 2TREATMENT 2PERIOD SINGLEDOSE CROSSOVER STUDY 2PART DESIGN TO EVALUATE THE BIOEQUIVALENCE AND TOLERABILITY OF TESTOSTERONE CYPIONATE FOLLOWING INTRAMUSCULAR IM INJECTION IN HEALTHY HYPOGONADAL MALE SUBJECTS" ($1.9M).